Z
ZENAS BIOPHARMA, INC. COMMON STOCK
NASDAQ: ZBIO (Zenas BioPharma, Inc.)
Last update: 2 days ago, 6:10PM14.63
-0.17 (-1.15%)
| Previous Close | 14.80 |
| Open | 14.81 |
| Volume | 84,361 |
| Avg. Volume (3M) | 171,620 |
| Market Cap | 612,034,368 |
| Price / Sales | 41.26 |
| Price / Book | 2.18 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 |
| Operating Margin (TTM) | -373.30% |
| Diluted EPS (TTM) | -3.89 |
| Total Debt/Equity (MRQ) | 0.43% |
| Current Ratio (MRQ) | 6.47 |
| Operating Cash Flow (TTM) | -137.62 M |
| Levered Free Cash Flow (TTM) | -77.73 M |
| Return on Assets (TTM) | -56.70% |
| Return on Equity (TTM) | -115.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Zenas BioPharma, Inc. | Bearish | - |
AIStockmoo Score
0.4
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.38 |
|
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 21.20% |
| % Held by Institutions | 74.88% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sr One Capital Management, Lp | 31 Mar 2025 | 4,911,539 |
| Enavate Sciences Gp, Llc | 31 Mar 2025 | 3,761,359 |
| Novo Holdings A/S | 31 Mar 2025 | 2,214,967 |
| Fairmount Funds Management Llc | 31 Mar 2025 | 1,892,806 |
| Vivo Capital, Llc | 31 Mar 2025 | 1,183,260 |
| Rock Springs Capital Management Lp | 31 Mar 2025 | 878,667 |
| 52 Weeks Range | ||
| Median | 30.00 (105.06%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 16 May 2025 | 30.00 (105.06%) | Buy | 10.47 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |